Clinical Trials
This section is intended to furnish veterinary professionals with a range of resources that focus on hemangiosarcoma. Our aim is to provide informative and beneficial materials that can support your work with both patients and clients.
Vaccine Study for Dogs with Splenic Hemangiosarcoma
The University of Florida College of Veterinary Medicine is currently recruiting dogs recently diagnosed with hemangiosarcoma for clinical research trial. This investigational trial is for the development of a vaccine for future treatment of splenic hemangiosarcoma in dogs.
AVMA Animal Health Studies Database – Hemangiosarcoma
Clinical studies in the AVMA Animal Health Studies Database. Detailed information about participation in the studies is available at the database site.
AAHSD005063 – Clinical evaluation of propranolol in combination with doxorubicin for the treatment of hemangiosarcoma
AAHSD005542: Use of the PI3K inhibitor copanlisib to treat splenic hemangiosarcoma, University of Pennsylvania.
AAHSD005546: Ethos Precision Medicine Umbrella Study for Hemangiosarcoma, University of Missouri.
AAHSD005266 – Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (Ethos-PUSH)
AAHSD005044 – Pharmacokinetics of a Novel Oil-Blend Rapamycin Formulation in Dogs with Cancer
Pathobiology of Hemangiosarcoma in Dogs: Research Advances and Future Perspectives
Veterinary Sciences
ISSN 2306-7381
Jong-Hyuk Kim 1,2,3,*, Ashley J. Graef 1,3, Erin B. Dickerson 1,2,3 and Jaime F. Modiano 1,2,3,4,5
Received: 27 August 2015 / Accepted 20 October 2015 / Published: 6 November 2015
Exploring new treatment options for a devastating cancer
Nicola Mason B.Vet.Med, PhD, DACVIM (Internal Medicine), FCPP, MRCVS, professor of medicine at the University of Pennsylvania School of Veterinary Medicine, examines the safety and efficacy of copanlisib—a phosphoinositide 3-kinase (PI3K) inhibitor—as a potential new treatment in the arsenal to slow the growth and spread of metastatic splenic hemangiosarcoma.
Recorded Webinar: Hemangiosarcoma: How to Predict Benign vs. Malignant Splenic Lesions & Manage Disease
As a small animal clinician, you are no stranger to the stress and frustration that accompany diagnoses of Hemangiosarcoma. To better understand how to recognize, diagnose, treat, and monitor cases of Hemangiosarcoma, join Rachel Venable, DVM, MS, DACVIM (Oncology) for this FREE 1-hr webinar. She will review all things related to this dangerous neoplasm. Dr. Venable will share important tips and bits of information to remember including next generation disease screening options.
Identification of genomic alterations with clinical impacting canine splenic hemangiosarcoma
Understanding the genomic landscape of HSA may aid in developing therapeutic strategies for dogs and may also inform therapies for the rare and aggressive human cancer angiosarcoma. The objectives of this study were to build a framework for leveraging real-world genomic and clinical data that could provide the foundation for precision medicine in veterinary oncology, and to determine the relationships between genomic and clinical features in canine splenic HSA.